Arrowhead Pharmaceuticals, Inc.ARWRNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

defenseworld.net

Arrowhead Pharmaceuticals Teases Q3 Data Wave: SHASTA-3/4, RNAi Dimer and ARO-MAPT Readouts Ahead

Arrowhead Pharmaceuticals (NASDAQ: ARWR) outlined a slate of expected clinical data updates during a discussion at the Leerink Partners Global Healthcare Conference in Miami, with management pointing to multiple readouts concentrated in the third quarter and additional updates expected in the second half of the year. Multiple clinical catalysts expected in the third quarter Chief Executive

defenseworld.net

Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Citigroup Inc.

Citigroup Inc. decreased its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 63.4% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 51,582 shares of the biotechnology company's stock after selling 89,204 shares during the period. Citigroup Inc.'s holdings in

gurufocus.com

GSK Strikes $1 Billion China RNA Deal

GSK plc (GSK) is making a calculated bet on next generation gene silencing drugs, signing a licensing agreement worth up to $1 billion with China's Frontier Bio

businesswire.com

Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026 Type: Fireside Chat Presentation Date/Time: March 2, 2026, 11:50 a.m. EST Leerink 2026 Global Healthcare Conference – March 8-11, 2026 Type: Fireside Chat Presentation Date/Time: March 9, 2026, 2:20 p.m. EST 2026 Jefferies Biotech on the Beach Summit – March 9-11, 2026.

defenseworld.net

China Universal Asset Management Co. Ltd. Acquires 14,497 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

China Universal Asset Management Co. Ltd. raised its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 52.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,234 shares of the biotechnology company's stock after acquiring an additional 14,497 shares during

defenseworld.net

Rhumbline Advisers Buys 11,115 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Rhumbline Advisers increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 3.1% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 371,112 shares of the biotechnology company's stock after purchasing an additional 11,115 shares during the quarter.

defenseworld.net

AlphaQuest LLC Sells 30,501 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

AlphaQuest LLC lessened its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 93.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,080 shares of the biotechnology company's stock after selling 30,501 shares during the quarter. AlphaQuest LLC's holdings

seekingalpha.com

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript

businesswire.com

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 first quarter ended December 31, 2025. The Company is hosting a conference call today, February 5, 2026, at 4:30 p.m. ET to discuss the results. “We had another quarter of strong execution across all areas of our business and we think Arrowhead is extremely well positioned to build on this progress throughout 2026 and beyond,” said Christopher Anzalone, Ph.D.,.

investopedia.com

Stock Market Today: Major Indexes, Bitcoin Drop as Risk-Off Sentiment Grips Markets; Dow Sheds 400 Points

Major stock indexes and bitcoin fell sharply Thursday amid broad risk-off sentiment, as investors weighed the latest Big Tech earnings and downbeat labor data.

prnewswire.com

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600: S&P MidCap 400 constituent Ciena Corp. (NYSE: CIEN) will replace Dayforce Inc. (NYSE: DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE: ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P.

fool.com

Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million

Privium Fund Management sold 75,747 shares of Arrowhead Pharmaceuticals in the fourth quarter; the estimated transaction value was $3.71 million based on quarterly average prices. Meanwhile, the position value increased by $10.09 million, reflecting both the sale and stock price movement during the quarter.

prnewswire.com

Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration

/PRNewswire/ -- USA News Group News Commentary - Global capital is officially rotating into "Longevity Infrastructure" which is now valued at a massive $27

businesswire.com

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (AP.

businesswire.com

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 5, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 first quarter ended December 31, 2026. Webcast and Conference Call Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately.

defenseworld.net

Bayforest Capital Ltd Decreases Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Bayforest Capital Ltd reduced its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 90.5% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,644 shares of the biotechnology company's stock after selling 53,759 shares during the period. Bayforest Capital Ltd's holdings

seekingalpha.com

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

fool.com

Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million?

CEO Christopher Anzalone sold 85,000 shares in the open market on Dec. 17, 2025, for a transaction value of ~$5,443,462. This sale represented 2.17% of Mr.

businesswire.com

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032 (the “notes”) and (ii) 3,100,776 shares of common stock, at a public offering price of $64.50 per share (or, in lieu of shares of common stock to certain investors, pre-funded warrants, at a public offering price of $64.499 per pre-funded warrant, for up to 1,550,.

businesswire.com

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease characterized by triglyceride levels that can be 10 to 100 times higher than normal leading to a substantially higher risk of developing acute, recurrent, and potent.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance